HIV evolution and diversity in ART-treated patients

Abstract Characterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods used to obtain and analyze intra-patient HIV sequence data, the accumulation of div...

Full description

Bibliographic Details
Main Authors: Gert van Zyl, Michael J. Bale, Mary F. Kearney
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Retrovirology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12977-018-0395-4
id doaj-2c4d1f48ac144c21abbd00d96517f916
record_format Article
spelling doaj-2c4d1f48ac144c21abbd00d96517f9162020-11-24T23:51:20ZengBMCRetrovirology1742-46902018-01-0115111210.1186/s12977-018-0395-4HIV evolution and diversity in ART-treated patientsGert van Zyl0Michael J. Bale1Mary F. Kearney2Division of Medical Virology, Stellenbosch University and NHLS TygerbergHIV Dynamic and Replication Program, Center for Cancer Research, National Cancer Institute at FrederickHIV Dynamic and Replication Program, Center for Cancer Research, National Cancer Institute at FrederickAbstract Characterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods used to obtain and analyze intra-patient HIV sequence data, the accumulation of diversity prior to ART and how it is affected by suppressive ART, the debate on viral replication and evolution in the presence of ART, HIV compartmentalization across various tissues, and mechanisms for the emergence of drug resistance. It also describes how CD4+ T cells that were likely infected with latent proviruses prior to initiating treatment can proliferate before and during ART, providing a renewable source of infected cells despite therapy. Some expanded cell clones carry intact and replication-competent proviruses with a small fraction of the clonal siblings being transcriptionally active and a source for residual viremia on ART. Such cells may also be the source for viral rebound after interrupting ART. The identical viral sequences observed for many years in both the plasma and infected cells of patients on long-term ART are likely due to the proliferation of infected cells both prior to and during treatment. Studies on HIV diversity may reveal targets that can be exploited in efforts to eradicate or control the infection without ART.http://link.springer.com/article/10.1186/s12977-018-0395-4HIV diversityAntiretroviral therapy (ART)HIV geneticsHIV replicationHIV reservoirHIV persistence
collection DOAJ
language English
format Article
sources DOAJ
author Gert van Zyl
Michael J. Bale
Mary F. Kearney
spellingShingle Gert van Zyl
Michael J. Bale
Mary F. Kearney
HIV evolution and diversity in ART-treated patients
Retrovirology
HIV diversity
Antiretroviral therapy (ART)
HIV genetics
HIV replication
HIV reservoir
HIV persistence
author_facet Gert van Zyl
Michael J. Bale
Mary F. Kearney
author_sort Gert van Zyl
title HIV evolution and diversity in ART-treated patients
title_short HIV evolution and diversity in ART-treated patients
title_full HIV evolution and diversity in ART-treated patients
title_fullStr HIV evolution and diversity in ART-treated patients
title_full_unstemmed HIV evolution and diversity in ART-treated patients
title_sort hiv evolution and diversity in art-treated patients
publisher BMC
series Retrovirology
issn 1742-4690
publishDate 2018-01-01
description Abstract Characterizing HIV genetic diversity and evolution during antiretroviral therapy (ART) provides insights into the mechanisms that maintain the viral reservoir during ART. This review describes common methods used to obtain and analyze intra-patient HIV sequence data, the accumulation of diversity prior to ART and how it is affected by suppressive ART, the debate on viral replication and evolution in the presence of ART, HIV compartmentalization across various tissues, and mechanisms for the emergence of drug resistance. It also describes how CD4+ T cells that were likely infected with latent proviruses prior to initiating treatment can proliferate before and during ART, providing a renewable source of infected cells despite therapy. Some expanded cell clones carry intact and replication-competent proviruses with a small fraction of the clonal siblings being transcriptionally active and a source for residual viremia on ART. Such cells may also be the source for viral rebound after interrupting ART. The identical viral sequences observed for many years in both the plasma and infected cells of patients on long-term ART are likely due to the proliferation of infected cells both prior to and during treatment. Studies on HIV diversity may reveal targets that can be exploited in efforts to eradicate or control the infection without ART.
topic HIV diversity
Antiretroviral therapy (ART)
HIV genetics
HIV replication
HIV reservoir
HIV persistence
url http://link.springer.com/article/10.1186/s12977-018-0395-4
work_keys_str_mv AT gertvanzyl hivevolutionanddiversityinarttreatedpatients
AT michaeljbale hivevolutionanddiversityinarttreatedpatients
AT maryfkearney hivevolutionanddiversityinarttreatedpatients
_version_ 1725476266809753600